Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cerebrovascular Diseases

• Publication date

  2013-09-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000353679PMID 24029780
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Database Evaluation of the Effects of Long‐Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes

  2011cited by this paper
• Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.

  2010cited by this paper
• Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.

  2010cited by this paper
• Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

  2010cited by this paper
• Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

  2010cited by this paper
• Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case‐control study

  2010cited by this paper
• Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre‐clinical systematic review

  2010cited by this paper
• Relationship between thiazolidinedione use and cardiovascular outcomes and all‐cause mortality among patients with diabetes: a time‐updated propensity analysis

  2009cited by this paper
• Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

  2009cited by this paper
• Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents.

  2009cited by this paper
• Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

  2009cited by this paper
• The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.

  2009cited by this paper
• Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients

  2009cited by this paper
• Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

  2008cited by this paper
• Association between serious ischemic cardiac outcomes and medications used to treat diabetes

  2008cited by this paper
• Pioglitazone and the Risk of Myocardial Infarction and Other Major Adverse Cardiac Events: A Meta-Analysis of Randomized, Controlled Trials

  2008cited by this paper
• Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Rosiglitazone for type 2 diabetes mellitus.

  2007cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007cited by this paper
• The Metabolic Syndrome and Cerebrovascular Disease: Suspicion and Evidence

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Rosiglitazone for type 2 diabetes mellitus.

  2007cited by this paper
• Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

  2007cited by this paper
• Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

  2007cited by this paper
• Vascular Protection in Brain Ischemia

  2006cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes

  2004cited by this paper
• Does universal health insurance make health care unaffordable? Lessons from Taiwan.

  2003cited by this paper

• Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study

  2025cites this paper
• Understanding the peroxisome proliferator-activated receptor gamma (PPAR-γ) role in periodontitis and diabetes mellitus: A molecular perspective.

  2025cites this paper
• Re-assessing the risk-benefit profile of Thiazolidinediones: Cardiovascular Risks and Stroke Prevention Through Real-World Data.

  2025cites this paper
• The General Principle of the Warburg Effect as a Possible Approach for Cancer Immunotherapy: The Regulatory Effect of Plant Extracts Could Change the Game

  2025cites this paper
• Thiazolidinediones Decrease the Recurrence of Intracerebral Hemorrhage in Type 2 Diabetes Mellitus Patients: A Nested Case-Control Study

  2024cites this paper
• Should methods of correction for multiple comparisons be applied in pharmacovigilance?

  2022cites this paper
• An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes

  2022influential citation
• Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case–control study

  2021cites this paper
• Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug

  2021cites this paper
• Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study

  2020cites this paper
• GLP-1 receptor agonists can reverse immunosuppression-induced beta-cell dysfunction

  2020cites this paper
• Tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534, a potent G protein-coupled receptor 40 (GPR40) agonist, at single- and multiple-ascending oral doses in healthy Chinese subjects

  2020cites this paper
• Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study

  2020cites this paper
• Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case–control study

  2019cites this paper
• Complex interaction of adiponectin-mediated pathways on cancer treatment: a novel therapeutic target

  2019cites this paper
• Neuroprotective effects of oleic acid in rodent models of cerebral ischaemia

  2019cites this paper
• Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we

  2019cites this paper
• Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis.

  2019cites this paper
• Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study

  2018cites this paper
• Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial

  2018cites this paper
• Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

  2017cites this paper
• Nuclear Receptors and the Adaptive Response of the Heart

  2017cites this paper
• Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair

  2017cites this paper
• Zinc finger transcription factor Sp7/Osterix acts on bone formation and regulates col10a1a expression in zebrafish.

  2017cites this paper
• Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.

  2017influential citation
• Effects of Incretin Mimetic Drugs on Diabetic Cardiovascular Functions

  2017cites this paper
• Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal

  2017cites this paper
• Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year Indian review.

  2016cites this paper
• Evolving role of adiponectin in cancer-controversies and update

  2016cites this paper
• Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study

  2016cites this paper
• Type 2 Diabetes and Hemorrhagic Stroke: A Population-Based Study in Spain from 2003 to 2012.

  2016cites this paper
• The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status12

  2015cites this paper
• Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins

  2015cites this paper
• Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes

  2015cites this paper
• Chapter 42 - Insulin, Other Hypoglycaemic Drugs, and Glucagon

  2014cites this paper
• Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?

  2014cites this paper
• Évaluation et analyse des représentations des professionnels de santé ambulatoires généralistes au sujet des incrétinomimétiques

  2014cites this paper
• The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies

  2014cites this paper
• Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.

  2014cites this paper
• State of the art: treatment of nonalcoholic steatohepatitis

  2014cites this paper
• Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

  2014cites this paper
• CMHX008, a Novel Peroxisome Proliferator-Activated Receptor γ Partial Agonist, Enhances Insulin Sensitivity In Vitro and In Vivo

  2014cites this paper
• Beneficial effects of Ginkgo biloba extract on insulin signaling cascade, dyslipidemia, and body adiposity of diet-induced obese rats

  2014cites this paper